JP2016512198A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512198A5
JP2016512198A5 JP2015561594A JP2015561594A JP2016512198A5 JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5 JP 2015561594 A JP2015561594 A JP 2015561594A JP 2015561594 A JP2015561594 A JP 2015561594A JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5
Authority
JP
Japan
Prior art keywords
independently selected
group
optionally substituted
hydrogen
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512198A (ja
JP6318180B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020700 external-priority patent/WO2014138212A1/en
Publication of JP2016512198A publication Critical patent/JP2016512198A/ja
Publication of JP2016512198A5 publication Critical patent/JP2016512198A5/ja
Application granted granted Critical
Publication of JP6318180B2 publication Critical patent/JP6318180B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561594A 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用 Expired - Fee Related JP6318180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773779P 2013-03-06 2013-03-06
US61/773,779 2013-03-06
PCT/US2014/020700 WO2014138212A1 (en) 2013-03-06 2014-03-05 CaMKII INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2016512198A JP2016512198A (ja) 2016-04-25
JP2016512198A5 true JP2016512198A5 (enExample) 2017-04-06
JP6318180B2 JP6318180B2 (ja) 2018-04-25

Family

ID=51491905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561594A Expired - Fee Related JP6318180B2 (ja) 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用

Country Status (7)

Country Link
US (1) US9951061B2 (enExample)
EP (1) EP2964225B1 (enExample)
JP (1) JP6318180B2 (enExample)
CN (1) CN105517549B (enExample)
AU (1) AU2014225889B2 (enExample)
CA (1) CA2901155C (enExample)
WO (1) WO2014138212A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11083444B2 (en) 2010-03-11 2021-08-10 Globus Medical, Inc. Tissue retractor and methods of use
WO2016037106A1 (en) 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
JP6532737B2 (ja) * 2015-04-01 2019-06-19 東ソー・ファインケム株式会社 ヘテロアセン化合物の製造方法
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
BR112020000258A2 (pt) * 2017-07-06 2020-07-14 Children's Medical Center Corporation composições e métodos para tratar ou prevenir taquicardia ventricular polimórfica catecolaminérgica
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
WO2024197267A1 (en) * 2023-03-22 2024-09-26 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof
US20250145630A1 (en) * 2023-11-07 2025-05-08 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033491A2 (en) 1997-01-31 1998-08-06 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
US7320959B2 (en) 2001-10-01 2008-01-22 Vanderbilt University Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
WO2004058764A1 (en) * 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
WO2006007422A2 (en) * 2004-06-16 2006-01-19 The Trustees Fo Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
US20080255121A1 (en) 2004-11-02 2008-10-16 Dainippon Sumitomo Pharma Co., Ltd. Combination Drug for Treating Autoimmune Disease
KR20080016643A (ko) * 2005-05-16 2008-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피롤로피리딘 유도체
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
WO2006131552A1 (de) * 2005-06-09 2006-12-14 Boehringer Ingelheim International Gmbh Alpha-carboline als cdk-1 inhibitoren
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2161271A1 (en) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2016512198A5 (enExample)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2013010792A5 (enExample)
JP2017534572A5 (enExample)
JP2016538257A5 (enExample)
JP2013545730A5 (enExample)
WO2015191506A3 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
JP2019524897A5 (enExample)
JP2010511701A5 (enExample)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
JP2017524733A5 (enExample)
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP2011518168A5 (enExample)
JP2022523702A (ja) トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
CO6341628A2 (es) \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\"
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2015522592A5 (enExample)
JP2014532751A5 (enExample)
JP2015515496A5 (enExample)
CN106458878B (zh) 2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
US20220411398A1 (en) Jnk inhibitors as anticancer agents
ES2531437T3 (es) Docosahexaenoato de pantenilo y su utilización para el tratamiento y la prevención de las enfermedades cardiovasculares